Research

Complementing the clinical excellence of the Nuclear Cardiac Imaging lab, Yale is involved in basic, translational and clinical research in noninvasive imaging. These studies include:

A Phase II Study of 99mTc-glucarate in Chest Pain Patients Suspected with Acute Coronary Symptoms (ACS) with No Obvious Signs of Acute Myocardial Infarction (AMI) and with Known Previous Coronary Artery Disease (CAD). Study involves dual isotope 99mTc-glucarate/201Tl imaging of patients presenting to our emergency department and chest pain center (CPC). (PI: A. Sinusas, NHLBI-sponsored)
Dynamic 82Rb PET imaging of absolute blood flow in patients post cardiac transplantation to detect early graft vasculopathy and optimization of immunosuppression (PI: A. Sinusas, ASNC-sponsored fellowship, A. Srivastava)
Regadenoson stress first pass and SPECT perfusion imaging in comparison with 3D echocardiography in patients at high risk for CAD to improve diagnostic accuracy (PI: A. Sinusas, Astellas-sponsored)
Dynamic 82Rb PET imaging of absolute blood flow in patients before and after implantation of a biventricular pacemaker for prediction of long term outcome (PI: S. Tandon, AHA-sponsored)
Phase 2 and 3 studies with a new F-18 labeled PET perfusion agent (18F-BMS747158-01). (PI: A. Sinusas, Lantheus-sponsored)
Validation of the Gated Blood Pool Single Photon Emission Computed Tomography (SPECT): Comparison to ERNA and 3D echocardiography (PI: A. Sinusas, investigator-sponsored)
A Phase I Open Label Pilot Study to Evaluate the Safety, Efficacy, and Tolerability of Anginera for Adults with Left Ventricular Dysfunction and Reversible Myocardial Ischemia undergoing CABG Surgery (PI: G. Tellides; Imaging PI: A. Sinusas, Theragen-sponsored)
Yale Fitness Intervention Trial (FIT) for health promotion in cancer survivors. (PI: T. Knopf, NIH NCI sponsored)
Measurement of matrix metalloproteinase activation post myocardial infarction. Evaluation of MR infarct size in relation to post-MI remodeling. (PI: A. Sinusas, investigator-sponsored)